Document Detail


Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation.
MedLine Citation:
PMID:  22027927     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Given our previous experience using dual-induction therapy with antithymocyte globulin (ATG)/daclizumab (Dac) (each with fewer doses than if used alone), we chose to compare two distinct dual-induction strategies.
METHODS: Single-center, open-label randomized trial of 200 primary kidney transplant recipients was performed: (group I, n=100) ATG/Dac (3 ATG, 2 Dac doses) versus (group II, n=100) ATG/alemtuzumab (1 dose each), with maintenance consisting of reduced tacrolimus dosing (rTd), enteric-coated mycophenolate sodium (EC-MPS), and early corticosteroid withdrawal. One half of standard EC-MPS dosing was targeted in group II to avoid severe leukopenia previously seen with alemtuzumab. The goal in both arms was to achieve rapid and effective lymphocyte depletion while simultaneously allowing reduced maintenance immunosuppression. Primary endpoint was the incidence of biopsy-proven acute rejection (BPAR).
RESULTS: With median follow-up of 38 months, there were no differences in BPAR rates: 14 of 100 vs. 13 of 100 (including borderline) and 10 of 100 vs. 9 of 100 (excluding borderline) in groups I and II, respectively (nonsignificant). Actuarial patient/graft survival at 48 months was 96%/91% in group I vs. 92%/83% in group II (N.S.). Mean estimated glomerular filtration rate (±standard error) at 36 months was 72.1±3.3 vs. 67.5±3.3 in groups I and II (N.S.). Greater incidence of leukopenia occurred in group II at month 1 only (P=0.002). Percentages having EC-MPS withheld/discontinued due to leukopenia, gastrointestinal symptoms, and infection were 12 of 100, 7 of 100, and 0 of 100 in group I vs. 19 of 100, 0 of 100, and 2 of 100 in group II, respectively (P=0.01). Rates of new onset diabetes mellitus after transplantation and infections were equally low in both groups (no lymphoproliferative disorders were observed).
CONCLUSIONS: These two distinct dual-induction therapies with rTd, EC-MPS, and planned early corticosteroid withdrawal resulted in favorable rates of BPAR and all secondary outcomes.
Authors:
Gaetano Ciancio; Jeffrey J Gaynor; Junichiro Sageshima; Giselle Guerra; Alberto Zarak; David Roth; Randolph Brown; Warren Kupin; Linda Chen; Lois Hanson; Lissett Tueros; Phillip Ruiz; Alan S Livingstone; George W Burke
Related Documents :
22958957 - 2-year patient-related versus stent-related outcomes: the sort out iv (scandinavian org...
21035077 - Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zon...
16650137 - Retinal nerve fiber layer and macular thickness in adolescents with epilepsy treated wi...
3551617 - Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic an...
22717777 - The impact of microsurgical clipping and endovascular coiling on the outcome of cerebra...
21431967 - Intraluminal radioactive stent compared with covered stent alone for the treatment of m...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Transplantation     Volume:  92     ISSN:  1534-6080     ISO Abbreviation:  Transplantation     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-14     Completed Date:  2012-03-20     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1348-57     Citation Subset:  IM    
Affiliation:
Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. gciancio@med.miami.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Cortex Hormones / administration & dosage
Adult
Antibodies, Monoclonal, Humanized / administration & dosage*
Antibodies, Neoplasm / administration & dosage*
Antilymphocyte Serum / administration & dosage*
Female
Follow-Up Studies
Graft Rejection / immunology,  prevention & control*
Humans
Immunoglobulin G / administration & dosage*
Immunosuppression*
Immunosuppressive Agents / administration & dosage
Kidney Transplantation*
Male
Tacrolimus / administration & dosage
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Antibodies, Monoclonal, Humanized; 0/Antibodies, Neoplasm; 0/Antilymphocyte Serum; 0/Immunoglobulin G; 0/Immunosuppressive Agents; 109581-93-3/Tacrolimus; 3A189DH42V/alemtuzumab; CUJ2MVI71Y/daclizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nitrosyl induces phosphorous-acid dissociation in ruthenium(ii).
Next Document:  Medication Phobia: A New Cause of Drug Noncompliance in Parkinson Disease.